Skip to main content
×
Home
    • Aa
    • Aa
  • The International Journal of Neuropsychopharmacology, Volume 6, Issue 4
  • December 2003, pp. 325-337

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

  • Siegfried Kasper (a1), Mark N. Lerman (a2), Robert D. McQuade (a3), Anutosh Saha (a4), William H. Carson (a5), Mirza Ali (a4), Donald Archibald (a3), Gary Ingenito (a4), Ronald Marcus (a3) and Teresa Pigott (a6)
  • DOI: http://dx.doi.org/10.1017/S1461145703003651
  • Published online: 01 December 2003
Abstract

Aripiprazole is a novel atypical antipsychotic for the treatment of schizophrenia. It is a D2 receptor partial agonist with partial agonist activity at 5-HT1A receptors and antagonist activity at 5-HT2A receptors. The long-term efficacy and safety of aripiprazole (30 mg/d) relative to haloperidol (10 mg/d) were investigated in two 52-wk, randomized, double-blind, multicentre studies (using similar protocols which were prospectively identified to be pooled for analysis) in 1294 patients in acute relapse with a diagnosis of chronic schizophrenia and who had previously responded to antipsychotic medications. Aripiprazole demonstrated long-term efficacy that was comparable or superior to haloperidol across all symptoms measures, including significantly greater improvements for PANSS negative subscale scores and MADRS total score (p<0.05). The time to discontinuation for any reason was significantly greater with aripiprazole than with haloperidol (p=0.0001). Time to discontinuation due to adverse events or lack of efficacy was significantly greater with aripiprazole than with haloperidol (p=0.0001). Aripiprazole was associated with significantly lower scores on all extrapyramidal symptoms assessments than haloperidol (p<0.001). In summary, aripiprazole demonstrated efficacy equivalent or superior to haloperidol with associated benefits for safety and tolerability. Aripiprazole represents a promising new option for the long-term treatment of schizophrenia.

Copyright
Corresponding author
O. Univ. Prof Dr Dr h.c. S. Kasper, Department of General Psychiatry, University of Vienna, A-1090 Vienna, Währinger Gürtel 18-20, Austria. Tel.: +43-1-40400 3568 Fax: +43-1-40400 3099 E-mail: sk@akh-wien.ac.at
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The The International Journal of Neuropsychopharmacology
  • ISSN: 1461-1457
  • EISSN: 1469-5111
  • URL: /core/journals/the-international-journal-of-neuropsychopharmacology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords: